Hengrui Medicine: Net profit expected to grow by 21.69% year-over-year in 2025, with a proposed dividend of 2 RMB per 10 shares

2026-03-27 06:02:32

People’s Finance News, March 25 - Heng Rui Medicine (600276) disclosed its annual report on March 25, achieving an operating income of 31.629 billion yuan in 2025, a year-on-year increase of 13.02%; the net profit attributable to shareholders is 7.711 billion yuan, a year-on-year increase of 21.69%; the basic earnings per share is 1.19 yuan. The company plans to distribute a cash dividend of 2 yuan (tax included) for every 10 shares. In 2025, the sales revenue of the company’s innovative drugs reached 16.342 billion yuan, a year-on-year increase of 26.09%, accounting for 58.34% of total drug sales revenue. The sales revenue of the innovative drugs covered by medical insurance, Ruvelizumab (second-generation AR antagonist) and Darsylis (CDK4/6 inhibitor), continues to maintain strong growth.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes